Quantitative measurement of anti-Scl-70 (anti-topoisomerase I) autoantibodies, which are often elevated in systemic sclerosis, particularly the diffuse form.
Scl-70-AK, quantitativ is often considered in the context of tiredness, reduced capacity, brain fog, or chronic exhaustion. This short overview clarifies what the marker can contribute, where its limits are, and when symptom or illness context becomes more important.
Scl-70-AK, quantitativ becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
Scl-70-AK, quantitativ does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
Anti-Scl-70 antibodies are autoantibodies directed against topoisomerase I, an enzyme involved in DNA replication. They are a hallmark biomarker for systemic sclerosis (scleroderma), especially the diffuse cutaneous subtype. Testing for these antibodies is part of the diagnostic workup for connective tissue diseases and may aid in disease classification. The test is often performed as a quantitative titer (e.g., 1:160) or as an enzyme-linked immunosorbent assay (ELISA) result. A negative result is typically defined as a titer below a certain cutoff, such as <1:100, though this varies by lab.
A low or negative result, typically a titer less than 1:100 (lab-dependent), is considered normal and suggests the absence of detectable anti-Scl-70 antibodies. This finding makes systemic sclerosis less likely, though low-titer false-negative results can occur, particularly in early disease or with certain assay methods.
A high or positive result, indicated by a titer at or above the laboratory’s cutoff (e.g., 1:100 or higher), suggests the presence of anti-Scl-70 antibodies. This is strongly associated with systemic sclerosis, especially the diffuse form, and may be associated with a higher risk of interstitial lung disease.
However, low positive titers can sometimes be found in other autoimmune conditions or even in healthy individuals, so results should be interpreted in the context of clinical findings.
This result is not specific for ME/CFS or Long COVID. Read it together with the clinical question, symptoms, related findings and the laboratory reference range rather than in isolation.
Practical details are separated from the general FAQ so they are easier to find.
Scl-70-AK, quantitativ becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
You now know which questions can matter when reading this result. With Elara you can keep the value and its surrounding context together over time.
Save the lab value with its date so individual measurements do not get lost.
See previous measurements together instead of relying on a single snapshot.
View Anti-Scl-70 Antibodies (Anti-Topoisomerase I), Quantitative alongside symptom, energy, sleep and PEM entries without assuming one caused the other.
Export your history as a PDF — structured for the next check-up.
Normally, anti-Scl-70 antibodies are undetectable or below the cutoff titer. A typical negative range is a titer of less than 1:100, but this cutoff is lab-dependent. Always check your laboratory’s reference range.
A positive anti-Scl-70 antibody test is strongly associated with systemic sclerosis, particularly the diffuse cutaneous subtype. It is found in approximately 20-30% of people with scleroderma. However, a positive result alone is not enough for a diagnosis; it must be interpreted alongside symptoms and other tests.
Anti-Scl-70 antibody titers can fluctuate, but they generally remain positive once they appear. There is some evidence that antibody levels may correlate with disease activity or organ involvement, but monitoring titers for disease management is not standard practice. Repeat testing is usually not necessary after a firm diagnosis.
Scl-70-AK, quantitativ does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
For many fatigue-related, inflammatory, hormonal, or recovery-linked markers, interpretation becomes stronger when symptoms, exertion response, and daily function are considered together.
Scl-70-AK, quantitativ is rarely meaningful in isolation when fatigue, brain fog, or unstable capacity are central. The fatigue hub provides the broader lab-and-symptom context.
If symptoms worsen after activity with a delay, PEM often explains more than an isolated lab value alone.
Questionnaires help connect biomarkers to symptom patterns, functional limits, and patient-reported change over time.
Markers from the same system can add useful context when a single lab value is hard to interpret on its own.
No individual medical review is documented.
This English content was created with AI assistance and automatically validated. This is not an individual medical review.
These references support the information presented on this page.
This information does not replace medical advice. Lab values should be assessed in the context of your medical history, the reason for testing and other findings. Elara provides health information for orientation — not diagnoses or treatment decisions.
Bring your lab values, symptoms and energy into one shared context — so you walk into your next appointment more informed and structured.
